Company Encyclopedia
View More
name
Adaptive Biotechnologies
ADPT.US
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient’s body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications.
770.89 B
ADPT.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Life Sciences Tools and ServicesIndustry
Industry Ranking29/60
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-37.18%E
    • Profit Margin-31.50%E
    • Gross Margin80.68%A
  • Growth ScoreB
    • Revenue YoY42.57%A
    • Net Profit YoY59.22%B
    • Total Assets YoY-12.16%E
    • Net Assets YoY-8.64%D
  • Cash ScoreC
    • Cash Flow Margin-317.48%D
    • OCF YoY42.57%A
  • Operating ScoreC
    • Turnover0.48C
  • Debt ScoreD
    • Gearing Ratio58.37%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Officer Robins Files To Sell 10,000 Of Adaptive Biotechnologies Corp [ADPT]

    Officer Robins Harlan S of Adaptive Biotechnologies Corp filed a Form 144 with the SEC to sell 10,000 shares on December 4, 2025, through Goldman Sachs & Co, under a prearranged trading plan (10b5-1).

    Reuters·
    US
    ADPT
    +1.93%
    Reuters·
    US
    ADPT
    +1.93%

    CFO Piskel Sells 162,820 ($3.2M) Of Adaptive Biotechnologies Corp [ADPT]

    CFO Kyle Piskel of Adaptive Biotechnologies Corp sold 162,820 shares worth $3.2 million, as disclosed in a Form 4 filed with the SEC. The transaction was part of a prearranged trading plan (10b5-1). Piskel exercised 110,114 shares before selling, with varying expiration dates. His ending holdings are 216,637 shares directly. The Washington Service provides insider trading analysis and data services.

    Reuters·
    US
    ADPT
    +1.93%
    Reuters·
    US
    ADPT
    +1.93%

    Adaptive Biotechnologies CEO and Chairman Chad M. Robins Reports Disposal of Common Shares

    Chad M. Robins, CEO and Chairman of Adaptive Biotechnologies Corporation, reported the disposal of common shares of the company. The full filing is available via EDGAR, the U.S. SEC's system. This news brief was created by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    ADPT
    +1.93%
    Reuters·
    US
    ADPT
    +1.93%

    Chmn Robins Files To Sell 124,998 Of Adaptive Biotechnologies Corp [ADPT]

    Chad M. Robins, Chairman of Adaptive Biotechnologies Corp, filed a Form 144 with the SEC to sell 124,998 shares on December 1, 2025, through Goldman Sachs under a prearranged trading plan (10b5-1). This filing allows the sale within 90 days.

    Reuters·
    US
    ADPT
    +1.93%
    Reuters·
    US
    ADPT
    +1.93%

    CFO Piskel Files To Sell 162,820 Of Adaptive Biotechnologies Corp [ADPT]

    Piskel Kyle, CFO of Adaptive Biotechnologies Corp, filed a Form 144 with the SEC to sell 162,820 shares on November 28, 2025, through Morgan Stanley Smith Barney LLC. This sale is executed under a prearranged trading plan (10b5-1). Filing Form 144 is required before selling restricted stock, allowing the sale within 90 days.

    Reuters·
    US
    ADPT
    +1.93%
    Reuters·
    US
    ADPT
    +1.93%
    © 2025 Longbridge｜Disclaimer